Thus, it remains to be determined whether the effects of SGF29 in ALT are direct, through recognition of telomeric chromatin, or indirect, via effects on gene expression, and whether targeting SGF29 could be effective or selective in ALT-positive cancers. The gene discussed is GPT; the disease is cancer.